Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. - Wikidata - awgldk - TriplyDB

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

http://www.wikidata.org/entity/Q45968266

about

Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry BF066, a novel dual target antiplatelet agent without significant bleeding Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database The safety of clopidogrel.Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischem The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Ac Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study.Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients.A bumpy and winding but right path to domestic drug-eluting coronary stents.Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Decision-making: stenting in acute myocardial infarction.Clopidogrel in acute coronary syndrome: implications of recent study findings.Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.Vascular disease: obesity and excess weight as modulators of risk.Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Use of cilostazol in percutaneous coronary interventions.Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.Clinical efficacy and safety of cilostazol: a critical review of the literature.Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.A case of stent thrombosis occurred at 5 years after sirolimus-eluting stent implantation.Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction.Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients.Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting.The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease.Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥75 years.'Smoker's paradox' in young patients with acute myocardial infarction.Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study.

P2860

Q26823633-9AF0D59B-B8C3-434C-BBDB-C486E099C128 Q27015211-3F3329B9-862B-473B-A93E-98437D1ABD72 Q27334889-E5605F7E-FFB1-46C7-832B-12ED662659CE Q28550517-1F0D46DA-224E-4C9C-A83E-6B7901869A24 Q33392895-34047A5C-EFAE-4749-86D0-4C97F78EEC87 Q33396814-613B3FEC-CCFE-4272-8120-C4A359224845 Q33426570-6F5EA6DF-EB59-48A4-9BA9-2C15DF4732BA Q33907206-DEB89DB3-769C-472F-A64A-11D07CA3B377 Q34114530-A248184D-DC8A-4F57-9CE5-40B5B9DFB7DE Q34451346-9601088B-8968-4F38-B606-B874746B822C Q36036395-59145942-007C-4EAD-8F0B-9F6DE350C637 Q36178172-1F9082A1-68CE-485C-B6BD-722EA2BC786D Q36360516-059C8A7B-BB2F-4F25-B2BC-A5AD0AF1311E Q37316783-D3EE3B83-ACBA-46A6-8F07-DF4EAF8FDA44 Q37408798-342C5ABD-177A-4475-A25E-77EACF0E8860 Q37627874-1640491A-62B2-40C2-9B09-925763E28B3B Q37749818-C8C0D274-6680-4D88-8C2F-2D1D097496E0 Q37786639-033877AE-1363-4923-B8DD-E1198991A09F Q37809122-D91C86DD-FB3A-416B-88D5-CD0756B0E121 Q37868586-426256EF-CC01-40D2-B865-947EAF1DAC70 Q37880741-B6DAB48F-C215-498A-837D-F0E6DBC186E4 Q37924998-B77581DC-6EEF-4CD4-AE7D-13CED5323D66 Q38012079-46F9775A-720D-44EF-96A6-3BA3A22D3B50 Q38016384-1189EFB8-D50D-4201-A1ED-708E847E04F4 Q38029492-9BAFA483-3EC7-4BB8-BA7B-7C1F658617B3 Q38122999-AC435A57-8D7C-42EE-9913-D883644D5AB7 Q38372990-CFC4438B-5D2D-48E2-BA37-431CF183E308 Q38403424-20C85FB4-9196-403A-94F8-15F9DC7ECC2F Q39051561-6003DC69-747C-4881-BC48-76D0655F341E Q39066560-97643800-B816-4E5E-9D4F-DBF3A9DCD660 Q39794388-8B81178F-94F3-44BC-BECE-4E3AC32E001C Q40774012-D905CCEC-6AAD-4E68-B356-ED9AC1CDCBA9 Q41352369-8A504A61-E447-408A-A6F9-5629F3EA893F Q41551745-16548995-D57A-44D9-A3CE-60CB2D59E3DD Q41826841-52A6D28E-DECC-4C4F-8BAF-226627B718B9 Q42372849-8E90EE2F-AAB6-42F3-B59B-2641D580EFE8 Q43841525-5A736779-374E-4E36-9D2D-39985D183298 Q45189184-09A84057-A767-42B7-B274-8DCCED3A5C80 Q45888145-8F7DCD61-A225-45F2-A94C-5BF566E5F9D5 Q47098635-B5FD01B6-33F8-4D87-9A3C-B18BA351736A

P2860

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

http://www.wikidata.org/entity/Q45968266

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Triple versus dual antiplatele ...... taneous coronary intervention.

@en

Triple versus dual antiplatele ...... taneous coronary intervention.

@nl

type

label

Triple versus dual antiplatele ...... taneous coronary intervention.

@en

Triple versus dual antiplatele ...... taneous coronary intervention.

@nl

prefLabel

Triple versus dual antiplatele ...... taneous coronary intervention.

@en

Triple versus dual antiplatele ...... taneous coronary intervention.

@nl

P1433

Q45968266-A972EB73-13FA-4895-8EEF-E4D95BC070C0

P1476

Q45968266-E89C4A27-1620-4E0D-AB1B-1207F7EC149D

P2093

Q45968266-0C3FCD56-E2C3-4D0B-832E-402CD87571CF

Q45968266-1148FDE3-5BED-444D-8FF5-690CACB3AB7B

Q45968266-12B412C7-1CC0-4C0D-A047-A342B063CD00

Q45968266-1A20E657-FB00-4E6E-B283-2C982C5D0A8C

Q45968266-2C766FF1-36A9-436E-9FA6-7128FB055073

Q45968266-2DA66471-FCC0-4E80-81F3-C70613BE40AA

Q45968266-3F335354-A63C-4B00-B449-5143EACF6FA4

Q45968266-420FF8C3-68F1-44D6-8466-5A5B2AA280CE

Q45968266-5D56A11D-2E6E-4B38-8A1C-69B9655FD453

Q45968266-5DF1AE85-5F55-4F7C-B72D-AF69F3C91F08

P304

Q45968266-2AB3F9F5-E57B-429C-B46D-891D5B826AAA

P31

Q45968266-5C461FB2-6209-4A0F-A0FE-F957B35CEBE4

P356

Q45968266-4ADBDD72-DC18-4916-81B6-D6CBEA3D74DE

P407

Q45968266-D0336452-6110-4712-9DE2-FA3FCA7DD833

P433

Q45968266-E00808ED-79A7-40A6-9B1F-F7BF177D2A1D

P478

Q45968266-6A11E888-DC5A-4844-A231-4CE0F7389060

P50

Q45968266-E69B31FC-CB8A-4C50-85C1-5F829C302A63

P577

Q45968266-48AA2D64-4973-4879-9DE0-D800F527C1FB

P5875

Q45968266-ECC7ABBC-D529-4BC4-960D-368375CA4CC8

P698

Q45968266-350A7648-21EE-4426-9600-96C3EAFBBF1B

P921

Q45968266-5F156FD3-6770-4C87-8CB8-D0D966CFD1A4

P356

CIRCULATIONAHA.108.822791

P1433

P1476

Triple versus dual antiplatele ...... taneous coronary intervention.

@en

P2093

Chang Gyu Park

http://www.w3.org/2001/XMLSchema#string

Chong Jin Kim

http://www.w3.org/2001/XMLSchema#string

Dong Hoon Choi

http://www.w3.org/2001/XMLSchema#string

Dong Joo Oh

http://www.w3.org/2001/XMLSchema#string

Eung Ju Kim

http://www.w3.org/2001/XMLSchema#string

Hong Seog Seo

http://www.w3.org/2001/XMLSchema#string

In Ho Chae

http://www.w3.org/2001/XMLSchema#string

In Whan Seong

http://www.w3.org/2001/XMLSchema#string

Jang Ho Bae

http://www.w3.org/2001/XMLSchema#string

Jei Keon Chae

http://www.w3.org/2001/XMLSchema#string

P304

3207-3214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.822791

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Kanhaiya L Poddar

P577

2009-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26293858

http://www.w3.org/2001/XMLSchema#string

P698

19528339

http://www.w3.org/2001/XMLSchema#string

P921